MedPath

Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Continuing Low Dose Aspirin Before Prostate Biopsy

Phase 4
Conditions
Complication
Interventions
First Posted Date
2016-04-20
Last Posted Date
2016-04-20
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
150
Registration Number
NCT02744937

Effects of Aspirin on Uterine Endometrial Repair Severe Intrauterine Adhesion

Not Applicable
Completed
Conditions
Intrauterine Adhesion
Interventions
Drug: Aspirin
Device: intrauterine balloon
First Posted Date
2016-04-20
Last Posted Date
2016-04-20
Lead Sponsor
First Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
114
Registration Number
NCT02744716
Locations
🇨🇳

the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)

Phase 4
Completed
Conditions
Acute Coronary Syndrome
Interventions
First Posted Date
2016-04-18
Last Posted Date
2021-03-17
Lead Sponsor
Sheffield Teaching Hospitals NHS Foundation Trust
Target Recruit Count
20
Registration Number
NCT02741817
Locations
🇬🇧

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Phase 3
Recruiting
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Other: No systemic corticosteroid
Other: No antiviral agent for COVID-19
Other: No immune modulation for COVID-19
Drug: Standard course macrolide
Other: No antiviral agent for influenza
Drug: Local standard venous thromboprophylaxis
Other: No immunoglobulin
Other: No simvastatin
Other: No cysteamine
Other: No Immune Modulator for Influenza
Other: No vitamin C
Other: No antiplatelet
Procedure: Clinician-preferred mechanical ventilation strategy
Other: No renin-angiotensin system inhibitor
Other: No endothelial modulator
Drug: Ceftriaxone
Drug: Eritoran
Drug: Moxifloxacin or Levofloxacin
Drug: Fixed-duration Hydrocortisone
Drug: Extended course macrolide
Drug: Five-days oseltamivir
Drug: Lopinavir / Ritonavir
Biological: Convalescent plasma
Drug: Angiotensin converting enzyme inhibitor
Drug: Nirmatrelvir/ritonavir
Drug: Therapeutic dose anticoagulation
Procedure: Protocolised mechanical ventilation strategy
Drug: Interferon beta-1a
Drug: Vitamin C
Drug: Simvastatin
Drug: Aspirin
Drug: Cysteamine
Drug: Imatinib
Drug: Angiotensin Receptor Blockers
Drug: Shock-dependent hydrocortisone
Drug: Ten-days oseltamivir
Drug: P2Y12 inhibitor
Drug: Conventional low dose thromboprophylaxis
Biological: Delayed administration of convalescent plasma
Drug: Piperacillin-tazobactam
Drug: Hydroxychloroquine
Drug: Anakinra
Drug: Apremilast
Drug: Baricitinib
Drug: Remdesivir
Drug: Hydroxychloroquine + lopinavir/ritonavir
Drug: Nirmatrelvir/ritonavir + remdesivir
Drug: Fixed-duration higher dose Hydrocortisone
Drug: Intermediate dose thromboprophylaxis
Drug: ARB + DMX-200
Drug: Ceftaroline
Drug: Baloxavir Marboxil
Drug: Tocilizumab
Drug: Fixed-duration dexamethasone
Drug: Amoxicillin-clavulanate
Drug: Five-days oseltamivir + baloxavir marboxil
Drug: Continuation of therapeutic dose anticoagulation
Drug: Ivermectin
Drug: Sarilumab
Drug: Ten-days oseltamivir + baloxavir marboxil
First Posted Date
2016-04-13
Last Posted Date
2024-07-12
Lead Sponsor
UMC Utrecht
Target Recruit Count
20000
Registration Number
NCT02735707
Locations
🇨🇦

Toronto Western Hospital, Toronto, Ontario, Canada

🇺🇸

University of Illinois Health, Chicago, Illinois, United States

🇦🇺

Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia

and more 405 locations

Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)

Phase 4
Completed
Conditions
Transcatheter Aortic Valve Replacement
Interventions
Drug: Vitamin K antagonist or direct oral anticoagulant treatment
Drug: Aspirin
First Posted Date
2016-04-13
Last Posted Date
2024-07-24
Lead Sponsor
Centre Hospitalier Universitaire de Nīmes
Target Recruit Count
170
Registration Number
NCT02735902
Locations
🇫🇷

Clinique du Millénaire, Montpellier cedex 2, France

🇫🇷

CHRU de Montpellier - Hôpital Arnaud de Villeneuve, Montpellier, France

🇫🇷

CH de Perpignan - Hôpital Saint Jean, Perpignan, France

and more 3 locations

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

Not Applicable
Completed
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
First Posted Date
2016-03-03
Last Posted Date
2021-07-01
Lead Sponsor
Duke University
Target Recruit Count
15076
Registration Number
NCT02697916
Locations
🇺🇸

New York University School of Medicine, New York, New York, United States

🇺🇸

Weill Cornell Medicine of Cornell University, New York, New York, United States

🇺🇸

University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States

and more 37 locations

Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection

Phase 4
Conditions
Angina
Interventions
Drug: Salvianolate injection
Drug: Aspirin
First Posted Date
2016-03-01
Last Posted Date
2016-03-01
Lead Sponsor
China Academy of Chinese Medical Sciences
Target Recruit Count
120
Registration Number
NCT02694848
Locations
🇨🇳

Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, Beijing, China

Aspirin in Young Psychotic Patients

Phase 2
Completed
Conditions
Psychosis
Acute Psychosis
Schizophrenia
Interventions
First Posted Date
2016-02-19
Last Posted Date
2020-01-31
Lead Sponsor
Clinic for Psychiatric Disorders, Dr Laza Lazarevic
Target Recruit Count
60
Registration Number
NCT02685748
Locations
🇷🇸

Clinic for psychiatric disorders Dr Laza Lazarevic, Belgrade, Serbia

Ticagrelor Versus Clopidogrel in Carotid Artery Stenting

Phase 2
Completed
Conditions
Carotid Artery Stenosis
Interventions
First Posted Date
2016-02-09
Last Posted Date
2022-06-28
Lead Sponsor
University Hospital, Basel, Switzerland
Target Recruit Count
210
Registration Number
NCT02677545
Locations
🇨🇭

Kantonsspital Aarau Klinik für Neurologie, Aarau, Switzerland

🇮🇹

Ospedale Civile di Mirano, Department of Cardiology, Mirano, Italy

🇧🇪

Ghent University Hospital - Dept thoracic and vascular surgery, Ghent, Belgium

and more 12 locations

Sildenafil Citrate for the Management of Asymmetrical Intrauterine Growth Restriction

Phase 2
Conditions
Intrauterine Growth Restriction
Interventions
First Posted Date
2016-02-09
Last Posted Date
2016-02-09
Lead Sponsor
Assiut University
Target Recruit Count
100
Registration Number
NCT02678221
Locations
🇪🇬

Faculty of Medicine, Assiut, Egypt

© Copyright 2025. All Rights Reserved by MedPath